Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | P2X purinoceptor 7 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | 6-phosphofructokinase | 0.1632 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0963 | 0.2852 | 0.5 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.0963 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1632 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.1604 | 0.9706 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.0963 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.1604 | 0.9706 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.1632 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1632 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.1604 | 0.9706 | 0.9706 |
Onchocerca volvulus | 0.1632 | 1 | 0.5 | |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1604 | 0.9706 | 0.9706 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.1632 | 1 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1632 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1604 | 0.9706 | 0.9604 |
Mycobacterium ulcerans | hypothetical protein | 0.0963 | 0.2852 | 0.5 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.0963 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.1632 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | Agonist activity at P2X7 in Sprague-Dawley rat synaptosome assessed as [3H]D-aspartate efflux preincubated at 10 to 50 uM for 8 mins by liquid scintillation counting | ChEMBL. | 24900736 | |
IC50 (binding) | = 7.7 uM | Antagonist activity at P2X7 in Sprague-Dawley rat synaptosome assessed as inhibition of BzATP-induced [3H]D-aspartate efflux compound preincubated for 8 mins by liquid scintillation counting | ChEMBL. | 24900736 |
Inhibition (binding) | Antagonist activity at P2X7 in Sprague-Dawley rat synaptosome assessed as inhibition of BzATP-induced [3H]D-aspartate efflux preincubated at 50 uM for 8 mins by liquid scintillation counting | ChEMBL. | 24900736 | |
Inhibition (binding) | Inhibition of COX-1 (unknown origin) | ChEMBL. | 24900736 | |
Inhibition (functional) | Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced abdominal contraction at 3 mg/kg, po measured after 30 mins | ChEMBL. | 24900736 | |
Inhibition (binding) | Antagonist activity at P2X7 in Sprague-Dawley rat synaptosome assessed as inhibition of BzATP-induced [3H]D-aspartate efflux preincubated at 50 uM for 8 mins by liquid scintillation counting in absence of extracellular Ca2+ | ChEMBL. | 24900736 | |
Inhibition (functional) | Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced abdominal contraction at 10 mg/kg, po measured after 30 mins in presence of naxolone | ChEMBL. | 24900736 | |
Inhibition (functional) | Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced abdominal contraction at 10 mg/kg, po measured after 30 mins in presence of SR-141716A | ChEMBL. | 24900736 | |
Inhibition (binding) | Inhibition of COX-2 (unknown origin) | ChEMBL. | 24900736 | |
Inhibition (binding) | Antagonist activity at P2X7 in Sprague-Dawley rat synaptosome assessed as inhibition of BzATP-induced [3H]D-aspartate efflux preincubated at 50 uM for 8 mins by liquid scintillation counting in presence of inhibitor of glutamate transporter Rose bengal | ChEMBL. | 24900736 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.